Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma

Francesco Lanza, Roberto M. Lemoli, Attilio Olivieri, Daniele Laszlo, Massimo Martino, Giorgina Specchia, Vincenzo Pavone, Manuela Imola, Annalisa Pasini, Giuseppe Milone, Ilaria Scortechini, Elisabetta Todisco, Elena Guggiari, Nicola Cascavilla, Giovanni Martinelli, Alessandro Rambaldi, Alberto Bosi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated. We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients. Study Design and Methods Two endpoints were established to define successful mobilization: patients with at least 2 × 106 CD34+ cells/kg collected by three leukapheresis procedures and patients achieving a peak count of at least 20 × 106 CD34+ cells/L during mobilization. Results Plerixafor achieved successful mobilization in both predicted (n = 64) and proven poor mobilizers (PMs; n = 143), classified according to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) criteria. Successful mobilization was independent of type of mobilization (steady state or chemotherapy); age; sex; disease; number or type of chemotherapy regimens preceding plerixafor; radiation therapy; prior treatment with melphalan, carmustine, lenalidomide, and radioimmune conjugates; and laboratory variables. Multivariate analysis identified previous fludarabine treatment and premobilization platelet count as predictors of successful mobilization. Conclusion This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy. Plerixafor can overcome negative effects of most predictors of poor mobilization to achieve satisfactory harvest both in predicted and proven PM.

Original languageEnglish
Pages (from-to)331-339
Number of pages9
JournalTransfusion
Volume54
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Multiple Myeloma
Lymphoma
Hematopoietic Stem Cell Mobilization
Drug Therapy
Granulocyte Colony-Stimulating Factor
Leukapheresis
Carmustine
Melphalan
Surveys and Questionnaires
JM 3100
Platelet Count
Radiotherapy
Multivariate Analysis
Databases
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy

Cite this

Factors affecting successful mobilization with plerixafor : An Italian prospective survey in 215 patients with multiple myeloma and lymphoma. / Lanza, Francesco; Lemoli, Roberto M.; Olivieri, Attilio; Laszlo, Daniele; Martino, Massimo; Specchia, Giorgina; Pavone, Vincenzo; Imola, Manuela; Pasini, Annalisa; Milone, Giuseppe; Scortechini, Ilaria; Todisco, Elisabetta; Guggiari, Elena; Cascavilla, Nicola; Martinelli, Giovanni; Rambaldi, Alessandro; Bosi, Alberto.

In: Transfusion, Vol. 54, No. 2, 02.2014, p. 331-339.

Research output: Contribution to journalArticle

Lanza, F, Lemoli, RM, Olivieri, A, Laszlo, D, Martino, M, Specchia, G, Pavone, V, Imola, M, Pasini, A, Milone, G, Scortechini, I, Todisco, E, Guggiari, E, Cascavilla, N, Martinelli, G, Rambaldi, A & Bosi, A 2014, 'Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma', Transfusion, vol. 54, no. 2, pp. 331-339. https://doi.org/10.1111/trf.12265
Lanza, Francesco ; Lemoli, Roberto M. ; Olivieri, Attilio ; Laszlo, Daniele ; Martino, Massimo ; Specchia, Giorgina ; Pavone, Vincenzo ; Imola, Manuela ; Pasini, Annalisa ; Milone, Giuseppe ; Scortechini, Ilaria ; Todisco, Elisabetta ; Guggiari, Elena ; Cascavilla, Nicola ; Martinelli, Giovanni ; Rambaldi, Alessandro ; Bosi, Alberto. / Factors affecting successful mobilization with plerixafor : An Italian prospective survey in 215 patients with multiple myeloma and lymphoma. In: Transfusion. 2014 ; Vol. 54, No. 2. pp. 331-339.
@article{a8e532cace6a4ecbb82f7967d75ec404,
title = "Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma",
abstract = "Background Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated. We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients. Study Design and Methods Two endpoints were established to define successful mobilization: patients with at least 2 × 106 CD34+ cells/kg collected by three leukapheresis procedures and patients achieving a peak count of at least 20 × 106 CD34+ cells/L during mobilization. Results Plerixafor achieved successful mobilization in both predicted (n = 64) and proven poor mobilizers (PMs; n = 143), classified according to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) criteria. Successful mobilization was independent of type of mobilization (steady state or chemotherapy); age; sex; disease; number or type of chemotherapy regimens preceding plerixafor; radiation therapy; prior treatment with melphalan, carmustine, lenalidomide, and radioimmune conjugates; and laboratory variables. Multivariate analysis identified previous fludarabine treatment and premobilization platelet count as predictors of successful mobilization. Conclusion This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy. Plerixafor can overcome negative effects of most predictors of poor mobilization to achieve satisfactory harvest both in predicted and proven PM.",
author = "Francesco Lanza and Lemoli, {Roberto M.} and Attilio Olivieri and Daniele Laszlo and Massimo Martino and Giorgina Specchia and Vincenzo Pavone and Manuela Imola and Annalisa Pasini and Giuseppe Milone and Ilaria Scortechini and Elisabetta Todisco and Elena Guggiari and Nicola Cascavilla and Giovanni Martinelli and Alessandro Rambaldi and Alberto Bosi",
year = "2014",
month = "2",
doi = "10.1111/trf.12265",
language = "English",
volume = "54",
pages = "331--339",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Blackwell Publishing Inc.",
number = "2",

}

TY - JOUR

T1 - Factors affecting successful mobilization with plerixafor

T2 - An Italian prospective survey in 215 patients with multiple myeloma and lymphoma

AU - Lanza, Francesco

AU - Lemoli, Roberto M.

AU - Olivieri, Attilio

AU - Laszlo, Daniele

AU - Martino, Massimo

AU - Specchia, Giorgina

AU - Pavone, Vincenzo

AU - Imola, Manuela

AU - Pasini, Annalisa

AU - Milone, Giuseppe

AU - Scortechini, Ilaria

AU - Todisco, Elisabetta

AU - Guggiari, Elena

AU - Cascavilla, Nicola

AU - Martinelli, Giovanni

AU - Rambaldi, Alessandro

AU - Bosi, Alberto

PY - 2014/2

Y1 - 2014/2

N2 - Background Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated. We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients. Study Design and Methods Two endpoints were established to define successful mobilization: patients with at least 2 × 106 CD34+ cells/kg collected by three leukapheresis procedures and patients achieving a peak count of at least 20 × 106 CD34+ cells/L during mobilization. Results Plerixafor achieved successful mobilization in both predicted (n = 64) and proven poor mobilizers (PMs; n = 143), classified according to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) criteria. Successful mobilization was independent of type of mobilization (steady state or chemotherapy); age; sex; disease; number or type of chemotherapy regimens preceding plerixafor; radiation therapy; prior treatment with melphalan, carmustine, lenalidomide, and radioimmune conjugates; and laboratory variables. Multivariate analysis identified previous fludarabine treatment and premobilization platelet count as predictors of successful mobilization. Conclusion This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy. Plerixafor can overcome negative effects of most predictors of poor mobilization to achieve satisfactory harvest both in predicted and proven PM.

AB - Background Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated. We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients. Study Design and Methods Two endpoints were established to define successful mobilization: patients with at least 2 × 106 CD34+ cells/kg collected by three leukapheresis procedures and patients achieving a peak count of at least 20 × 106 CD34+ cells/L during mobilization. Results Plerixafor achieved successful mobilization in both predicted (n = 64) and proven poor mobilizers (PMs; n = 143), classified according to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) criteria. Successful mobilization was independent of type of mobilization (steady state or chemotherapy); age; sex; disease; number or type of chemotherapy regimens preceding plerixafor; radiation therapy; prior treatment with melphalan, carmustine, lenalidomide, and radioimmune conjugates; and laboratory variables. Multivariate analysis identified previous fludarabine treatment and premobilization platelet count as predictors of successful mobilization. Conclusion This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy. Plerixafor can overcome negative effects of most predictors of poor mobilization to achieve satisfactory harvest both in predicted and proven PM.

UR - http://www.scopus.com/inward/record.url?scp=84894066812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894066812&partnerID=8YFLogxK

U2 - 10.1111/trf.12265

DO - 10.1111/trf.12265

M3 - Article

C2 - 23781769

AN - SCOPUS:84894066812

VL - 54

SP - 331

EP - 339

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 2

ER -